In this article, we will discuss about Avelumab (Dosage Overview). So, let’s get started.
Indications
Metastatic Merkel Cell Carcinoma
Avelumab (BAVENCIO®) is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Locally Advanced or Metastatic Urothelial Carcinoma
First-Line Maintenance Treatment of Urothelial Carcinoma
Avelumab (BAVENCIO®) is indicated for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.
Previously-Treated Urothelial Carcinoma
Avelumab (BAVENCIO®) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) who:
• Have disease progression during or following platinum-containing chemotherapy
• Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Advanced Renal Cell Carcinoma
Avelumab (BAVENCIO®) in combination with axitinib is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Dosage
Premedication
Premedicate patients with an antihistamine and with acetaminophen prior to the first 4 infusions of Avelumab (BAVENCIO®). Premedication should be administered for subsequent Avelumab (BAVENCIO®) doses based upon clinical judgment and presence severity of prior infusion reactions.
Recommended Dosage for MCC
The recommended dose of Avelumab (BAVENCIO®) is 800 mg administered as an intravenous 60 minutes every 2 weeks until disease progression or unacceptable toxicity.
Recommended Dosage for UC
The recommended dose of Avelumab (BAVENCIO®) is 800 mg administered as an intravenous infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity.
Recommended Dosage for RCC
The recommended dose of Avelumab (BAVENCIO®) is 800 mg administered as an intravenous infusion over 60 minutes every 2 weeks in combination with axitinib 5 mg orally taken twice daily (12 hours apart) with or without food until disease progression or unacceptable toxicity. When axitinib is used in combination with Avelumab (BAVENCIO®), dose escalation of axitinib above the initial 5 mg dose may be considered at intervals of two weeks or longer.
Adverse Reactions
Most common adverse reactions (≥20%) in patients were:
• MCC: fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related
reaction, rash, decreased appetite, and peripheral edema.
• UC:
• Maintenance treatment: fatigue, musculoskeletal pain, urinary tract
infection, and rash.
• Previously-treated: fatigue, infusion-related reaction, musculoskeletal pain, nausea, decreased appetite, and urinary tract infection.
• RCC (with axitinib): diarrhea, fatigue, hypertension, musculoskeletal pain, nausea, mucositis, palmar-plantar erythrodysesthesia, dysphonia, decreased appetite, hypothyroidism, rash, hepatotoxicity, cough, dyspnea, abdominal pain, and headache.